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Background: Polycystin-2 (PC2), encoded by the gene that is mutated in autosomal dominant polycystic kidney
disease (ADPKD), functions as a calcium (Ca2+) permeable ion channel. Considerable controversy remains regarding
the subcellular localization and signaling function of PC2 in kidney cells.
Methods: We investigated the subcellular PC2 localization by immunocytochemistry and confocal microscopy in
primary cultures of human and rat proximal tubule cells after stimulating cytosolic Ca2+ signaling. Plasma membrane
(PM) Ca2+ permeability was evaluated by Fura-2 manganese quenching using time-lapse fluorescence microscopy.
Results: We demonstrated that PC2 exhibits a dynamic subcellular localization pattern. In unstimulated human or rat
proximal tubule cells, PC2 exhibited a cytosolic/reticular distribution. Treatments with agents that in various ways affect
the Ca2+ signaling machinery, those being ATP, bradykinin, ionomycin, CPA or thapsigargin, resulted in increased PC2
immunostaining in the PM. Exposing cells to the steroid hormone ouabain, known to trigger Ca2+ oscillations in kidney
cells, caused increased PC2 in the PM and increased PM Ca2+ permeability. Intracellular Ca2+ buffering with BAPTA,
inositol 1,4,5-trisphosphate receptor (InsP3R) inhibition with 2-aminoethoxydiphenyl borate (2-APB) or Ca
2+/Calmodulin-
dependent kinase inhibition with KN-93 completely abolished ouabain-stimulated PC2 translocation to the PM.
Conclusions: These novel findings demonstrate intracellular Ca2+-dependent PC2 trafficking in human and rat kidney
cells, which may provide new insight into cyst formations in ADPKD.
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Autosomal dominant polycystic kidney disease (ADPKD)
is the most commonly inherited monogenetic disease,
affecting more than 1 in 1000 live births, causing renal
failure [1]. ADPKD is caused by mutation in two asso-
ciated proteins, polycystin-1 or −2 (PC1 and PC2), which
are essential for the formation and maintenance of a
proper structure of the renal tubule. These mutations in
PC1 and PC2 are responsible for approximately 85% and
15% of all ADPKD cases, respectively [2]. It is well estab-
lished that PC2 acts as an ion channel permeable to cal-
cium ions (Ca2+) [3]. Interestingly, loss of PC2 channel
function and subsequent impaired Ca2+ signaling may
contribute to ADPKD pathogenesis [4]. A controversial
aspect of PC2-mediated signaling in ADPKD is whether* Correspondence: per.uhlen@ki.se
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reproduction in any medium, provided the orthis protein is expressed in the endoplasmic reticulum
(ER) or in the plasma membrane (PM). The amount of
PC2 present in the ER, where it functions as a Ca2+-acti-
vated intracellular Ca2+ release channel [3], is signifi-
cantly larger than the amount of PC2 expressed in the
PM, where it functions as a non-selective cation channel
[5,6]. In addition, PC2 has also been documented in the
primary cilium of kidney epithelial cells, where it contri-
butes to the mechano-sensing machinery by mediating
Ca2+ entry in response to flow rate changes [7]. Never-
theless, the exact function and mechanism of PC2
activation in the cilium and/or other subcellular orga-
nelles remain largely unknown.
Ca2+ signaling is a vital mechanism in many cell types,
controlling diverse cellular processes, such as: secretion,
mechano-transduction, cell death, gene expression, or
proliferation (for review see [8]). Under certain conditions,
via a sophisticated interplay between Ca2+ channels andral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of internal organelles, such as the ER, sustained oscillatory
Ca2+ signaling can occur [9]. These Ca2+ oscillations en-
code important information in their frequency and ampli-
tude, which is decoded by cells using different Ca2+-effectors,
such as protein kinases, phosphatases, proteases or tran-
scription factors, which in turn regulate adaptive cellular
responses. Intracellular Ca2+ signaling mishandling is
involved in the pathogenesis or progression of several dis-
ease conditions and particularly in kidney disease, where
intracellular Ca2+ signaling appears to be linked to cystic
formation during ADPKD [10].
In the current study, we investigated the dynamic na-
ture of PC2 localization in primary human and rat
kidney proximal tubule cells. We found that PC2 trans-
locates from a basal, reticular-like localization to a PM
localization when cells were challenged with agents that
raise the basal concentration of intracellular Ca2+. PC2
trafficking was inhibited either by intracellular Ca2+ re-
lease blockers or by inhibitors of key Ca2+-dependent
proteins. Taken together, these results demonstrate that
PC trafficking in kidney cells is regulated by intracellular
Ca2+ and may contribute to the general understanding
of ADPKD.Methods
Cells cultures
Primary cultures of rat proximal tubule (rPT) cells
were prepared as described previously [11]. Briefly,
kidneys from 20-day-old female Sprague Dawley rats
were used to prepare rPT cells. Cells were cultured in
supplemented DMEM (20 mM Hepes, 24 mM
NaHCO3, 10 mg/ml penicillin, 10 mg/ml strepto-
mycin and 10% fetal bovine serum (FBS)) on glass
coverslips for 48–72 h in 5% CO2 at 37°C. Cells were
starved in 1% FBS and cultured in the absence of
antibiotics for 24 h before the experiment. Primary
cultures of human proximal tubule (hPT) cells were
prepared as described. Briefly, approximately 10 g of
fresh renal tissue, obtained from human nephrectomy
samples, was dissected, and the obtained cortex was
minced and then enzymatically digested with 1 mg/ml
of type 4 collagenase. The resulting suspension was
filtered and then centrifuged at 200 x g for 5 min.
The pellet was washed three times with ice-cold
Hank’s balanced salt solution and finally resuspended
in DMEM/Ham’s Nutrient Mixture F12, supplemen-
ted with 10% FBS, insulin-transferrin-selenium, hydro-
cortisone and antibiotics. The final cell suspension
was then plated onto coverslips coated with type IV
collagen. All experiments were ethically approved by
the Swedish Ethical Committee North, numbers 183/03
(rat) and 03–143 (human).Reagents
Reagents and concentrations were as follows: ouabain
(1 μM for hPT cells and 100 μM for rPT cells since
rodents are more resistant to ouabain than humans
[12], Sigma-Aldrich), ATP (25 μM, Sigma-Aldrich),
bradykinin (20 nM, Sigma-Aldrich), ionomycin (1 μM,
Sigma-Aldrich), thapsigargin (1 μM, Sigma-Aldrich), bis
(2-aminophenoxy)ethane tetraacetic acid (BAPTA, 10
μM, Molecular Probes), 2-aminoethoxydiphenyl borate
(2-APB, 100 μM, Sigma-Aldrich), KN-93 (10 μM, Sigma-
Aldrich), LY294002 (10 μM, Sigma-Aldrich), wortmanin
(5 μM, Sigma-Aldrich), FK506 (20 nM, Sigma-Aldrich),
Go6983 (1 μM, Sigma-Aldrich), calphostin (5 μM,
Sigma-Aldrich), and cycloheximide (CHX, 100 μM,
Sigma-Aldrich). Cells were treated with inducers of Ca2+
signaling (ouabain, ATP, bradykinin) 3 h prior immunos-
taining and with inhibitors 15 min prior Ca2+ signaling-
inducers.
Immunocytochemistry
Immunocytochemistry of PC2 in hPT and rPT cells was
performed according to standard protocol. Cells were
fixed with 4% paraformaldehyde for 15 min and then
permeabilized for 10 min with 0.3% Triton X-100. After
blocking with 1% BSA for 1 h, cells were incubated over-
night at 4°C with anti-PC2 polyclonal antibodies (gene-
rously provided by Dr. Stefan Somlo, Department of
Internal Medicine, Yale University School of Medicine,
New Haven, CT, USA and Dr. Jing Zhou, Renal Division,
Department of Medicine, Brigham and Women’s Hos-
pital and Harvard Medical School, Boston, MA, USA)
against amino acids 103 to 203 (YCB9) [13] or amino
acids 44 to 62 [7] on the N-terminus, respectively. Both
antibodies showed similar PC2 pattern in proximal tu-
bule cells (Additional file 1: Figure S1). All images pre-
sented here are using the antibody against YCB9. Cells
were incubated for 1 h at room temperature with
Alexa488 fluorescent secondary antibody (1:500, Mo-
lecular Probes). Staining with only secondary antibody
was used as control (Additional file 2: Figure S2). Slides
were scanned with similar exposure time using a Leica
TCS SP inverted confocal laser scanning microscope
equipped with a 40x/1.4 NA oil-immersion objective.
Calcium imaging
For Ca2+ experiments cells were loaded with 5 μM Fura-
2/AM (Invitrogen) at 37°C for 1 h. Calcium measure-
ments were performed at 37°C in a heated chamber
(QE-1, Warner Instruments) with a cooled CCD camera
(ORCA-ERG, Hamamatsu) mounted on an upright
microscope (Axioskop 2 FS, Zeiss) equipped with a
40x/0.8 NA water dipping lens. Excitation at 340 and
380 nm was carried out with a monochromator
(Polychrome IV, TILL Photonics). Devices were
Figure 1 PC2 trafficking to the PM in human proximal tubule
(hPT) cells. (A-F). Immunocytochemistry of PC2 in hRT cells treated
with control (A), 1 μM ouabain (C), or 25 μM ATP (E). Scale bars, 20
μm. Localization profile of PC2 along a line (as indicated) through
the center of a single hPT cell treated with control (B), ouabain (D),
or ATP (F). Gray areas represent PM regions. (G) Quantitative analysis
of a number of PM PC2-positive hRT cells following indicated
treatments. Values are the mean ± SEM, and ***P < 0.001 vs. control.
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computer software MetaFluor (Molecular Devices). All
experiments were performed in physiological buffer
(100 mM NaCl, 4 mM KCl, 25 mM NaHCO3, 1.5 mM
CaCl2, 1.1 mM MgCl2, 1 mM NaH2PO4, 10 mM
D-glucose, and 20 mM HEPES, pH 7.4). An oscillating
cell was defined as a cell that displayed two or more
Ca2+ peaks, of which each peak’s amplitude was at least
10% over baseline. PM permeability was measured
using the Fura-2 fluorescence quenching technique with
Mn2+. Fura-2 was then excited at the Ca2+-dependent
wavelength, 340 nm, and at the Ca2+-independent
wavelength, 360 nm. The PM Ca2+ permeability was
measured as the fluorescence decrease after adding
0.1 mM MnC12 to the recording medium.
Statistics
PM PC2-positive cells were counted and expressed as
the percentage over the total number of cells. The per-
centage of PM-positive cells corresponding to the con-
trol condition was assigned a value of 1, and the
different treatments were normalized over this value in
order to express them as fold-values over control. Data
are presented as mean ± SEM or as a representative re-
sult of at least three independent experiments. One-way
ANOVA with a Bonferroni post hoc test was used and
significance was accepted at P < 0.05.
Results
Subcellular localization of PC2 is dynamically regulated
The subcellular localization of the PC2 protein was stud-
ied using immunocytochemistry in human primary prox-
imal tubule (hPT) cells prepared from nephrectomy
patients, as described in Materials and methods. In
un-stimulated hPT cells PC2 exhibited a cytoplasmic/
reticular staining (Figure 1A), in good agreement with
a previous report [3]. Plotting the localization profile
along a line through an individual cell confirmed the
cytoplasmic/reticular localization pattern (Figure 1B).
To test the dynamic nature of PC2 localization, hPT
cells were challenged with the steroid ouabain, known
to induce intracellular Ca2+ oscillations in rat kidney
cells [14,15]. When hPT cells were exposed to oua-
bain, a strong PC2 localization in the PM was
observed (Figure 1C and D). To test whether this ef-
fect was due to an increase of cytosolic Ca2+, hPT
cells were treated with nucleotide adenosine triphos-
phate (ATP), a well-established inducer of cytosolic
Ca2+ signaling in renal cells [16]. hPT cells exposed
to ATP exhibited a clear translocation of PC2 towards
the PM (Figure 1E and F). Quantification analysis of
n single-cells from N independent preparations
showed that the number of hPT cells positive for PC2
in the PM was significantly increased 5.3 ± 1.0-fold byouabain and 6.0 ± 1.1-fold by ATP (control n = 76 N = 6,
ouabain n = 159 N = 7, ATP n = 70 N = 4) (Figure 1G).
Next, the dynamic localization pattern of PC2 in rat
kidney cells was investigated. Immunocytochemistry
experiments in primary cultures of rat proximal tubule
(rPT) cells showed a cytoplasmic/reticular localization
pattern of PC2 in un-stimulated cells (Figure 2A and B),
Figure 2 PC2 trafficking to the PM in rat proximal tubule (rPT)
cells. (A-F) Immunocytochemistry of PC2 in rPT cells treated with
control (A), 100 μM ouabain (C), or 20 nM bradykinin (E). Scale bars,
20 μm. Localization profile of PC along a line (as indicated) through
the center of a single rPT cell treated with control (B), ouabain (D),
or bradykinin (F). Gray areas represent PM regions. (G) Quantitative
analysis of a number of PM PC2 positive rPT cells following indicated
treatments. Values are the mean ± SEM and ***P < 0.001 vs. control.
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PC2 localization was clearly translocated towards the PM
when rPT cells were treated with ouabain (Figure 2C and D)
or bradykinin (Figure 2E and F). Both ouabain and bradyki-
nin are reported to induce a Ca2+ response in rPT cells
[15]. Quantitative analysis showed that the number of rPT
cells positive for PC2 in the PM was significantly increased
11.7 ± 2.1-fold by ouabain and 10.1 ± 2.2-fold by bradykinin(control n = 175 N = 8, ouabain n = 123 N = 7, bradykinin
n = 104 N = 5) (Figure 2G).
To test whether an increase of the cytosolic Ca2+ con-
centration was sufficient to induce PC2-trafficking
towards the PM, rPT cells were exposed to various well-
known agents affecting the cellular Ca2+ machinery.
First, a Ca2+ influx was induced by using the Ca2+ iono-
phore ionomycin. Ionomycin caused a significant 10.1 ±
0.6-fold increase of PC2 PM positive rPT cells (control
n = 175 N = 8, ionomycin n = 139 N = 8) (Figure 3A). In
another approach, a transient Ca2+ release from the ER
was induced by using thapsigargin, an inhibitor of
the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase,
which caused a raise in cytosolic Ca2+. Thapsigargin
stimulated a significant 6.4 ± 1.3-fold increase of PC2
translocation to the PM in rPT cells (thapsigargin n = 73
N = 6) (Figure 3B). The stimulatory effect of thapsigargin
on PC2 trafficking was 1.9 ± 1.0-fold and reversed in
cells pre-incubated with BAPTA (thapsigargin + BAPTA
n = 76 N = 7), an intracellular Ca2+ chelator (Figure 3B).
Taken together, these results demonstrate that cyto-
solic Ca2+ regulates PC2 trafficking in both human and
rat kidney cells.
Ca2+ channels in the PM are more abundant in Ca2+
oscillating cells
A functional study of the PM Ca2+ permeability was
then conducted using the manganese (Mn2+) quench-
ing technique, based on the higher affinity Fura-2 has
for Mn2+ than for Ca2+. When Mn2+ binds to Fura-2,
it displaces Ca2+, resulting in a decreased fluorescence
emission signal. Fura-2 preloaded rPT cells were first
treated with ouabain and monitored using time-lapse
Ca2+ imaging. Subsequent addition of Mn2+ to the
recording medium induced a rapid decrease in the
Fura-2 emission signal (Figure 3C). Interestingly, cells
that were responding to ouabain with cytosolic Ca2+
oscillations showed a significantly steeper decrease
in Fura-2 fluorescence compared to that of non-
oscillating cells (Figure 3D). These results indicate an
increased amount of Ca2+ channels present in the PM
of cells exhibiting ouabain-induced Ca2+ oscillations.
Dynamic localization of PC2 is regulated by cytosolic Ca2+
signaling
To further investigate the contribution of cytosolic
Ca2+ signaling on PC2-trafficking, immunocytochem-
istry experiments were conducted on rPT cells stimu-
lated with ouabain in the presence of intracellular
Ca2+ signaling inhibitors. First, the InsP3R pathway
was inhibited using 2-APB. In the absence of 2-APB,
ouabain caused a significant 11.7 ± 1.3-fold increase of
PC2 translocation to the PM (control n = 175 N = 8,
ouabain n = 74 N = 4), while pre-incubation with 2-APB
Figure 3 Intracellular Ca2+ release mediates PC2 translocation to the PM. (A-B) Quantitative analysis of a number of PM PC2-positive rPT
cells following treatment with 1 μM ionomycin (A), 1 μM thapsigargin (Tg) (B), or thapsigargin with 10 μM BAPTA (B). (C) Single cell Ca2+
recording of two rPT cells loaded with Fura-2/AM treated with 100 μM ouabain followed by sequential addition of 2 mM Mn2+ to the recoding
medium. (D) Statistical analysis of slope decrease in non-oscillating (gray bar) and oscillating cells (black bar) in response to ouabain after Mn2+
addition to the recording medium. Values are the mean ± SEM, *P < 0.05, ***P < 0.001 vs. control, and #P < 0.001 vs. treatment.
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induced PC2 PM trafficking (ouabain n = 123 N = 7,
ouabain + 2-APB n = 94 N = 4) (Figure 4A). Next, cytosolic
Ca2+ was buffered using BAPTA. This treatment
completely blocked the PC2 trafficking to the PM induced
by ouabain (0.8 ± 0.7-fold, ouabain n = 123 N= 7, ouabain +
BAPTA n = 56 N = 4) (Figure 4B). Together, these results
suggest a pivotal role of InsP3R in triggering cytosolic
Ca2+-dependent PC2 trafficking.
Ca2+-dependent protein kinases are involved in dynamic
PC2 localization
To investigate the involvement of Ca2+-sensitive kinases
on PC2 trafficking, selective chemical inhibitors were
used. Under control conditions, ouabain induced a signifi-
cant 12.4 ± 1.3-fold translocation of PC2 to the PM
(ouabain n = 114 N = 5) (Figure 4C). A common target for
Ca2+ signaling in mammalian cells is Ca2+/Calmodulin-
dependent kinase (CaMK). Selective inhibition of CaMK
with KN93 completely blocked the ouabain-induced PC2
trafficking to the PM (1.2 ± 0.9-fold, ouabain + KN93
n = 104 N = 7) (Figure 4C). The contribution of the Phos-
phatidylinositol 3-kinase (PI3K)/Akt pathway was next
investigated. Pre-incubation with LY294002 or wortmaninalso produced a significant decrease in ouabain-induced
PC2 translocation (6.9 ± 1.5-fold, ouabain + LY294002
n = 72 N = 4 and 4.8 ± 1.4-fold, ouabain +wortmanin n = 92
N= 4, respectively) (Figure 4C). Inhibition of protein kinase
C (PKC) by means of broad spectrum PKC inhibitors
Go6983 or calphostin resulted in decreased levels of PC2
staining in the PM that reached statistical significance only
in Go6983 pre-treated cells (8.4 ± 1.0-fold, ouabain +
Go6983 n= 117 N= 6 and 9.9 ± 1.7-fold, ouabain + calphos-
tin n = 67 N = 3) (Figure 4C). Finally, inhibition of the
Ca2+-dependent protein-phosphatase calcineurin with FK506,
had no effect on the PC2 translocation (11.4 ± 1.0-fold,
ouabain + FK506 n=124 N=7) (Figure 4C).
The observed increase in the PC2 immunosignal
from the PM could be due to di novo synthesis of
PC2 proteins. To investigate this hypothesis, cells
were pre-treated with cycloheximide (CHX) to stop
the translation of new proteins. Pre-treatment of cells
with CHX failed to stop increased PC2 trafficking to
the PM following ouabain treatment (11.4 ± 0.8-fold,
ouabain + CHX n = 51 N = 3) (Figure 4C).
Together, these results suggest a translocation of cellu-
lar PC2 to the PM via the intracellular Ca2+/CaMK path-
way, with some involvement of the PI3K/Akt and PKC
pathways.
Figure 4 PC2 trafficking to the PM depends on intracellular Ca2+ signaling and Ca2+-dependent kinases. (A-B) Quantitative analysis of PM
PC2-positive rPT cells following treatment with 100 μM ouabain with 100 μM 2-APB (A), with 10 μM BAPTA (B), or with 10 μM KN-93, 10 μM
LY294002, 5 μM wortmanin, 20 nM FK506, 1 μM Go6983, 5 μM calphostin, or 100 μM cycloheximide (C). Values are the mean ± SEM, ***P < 0.001
vs. control, and #P < 0.001 vs. treatment.
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The notion that polycystin proteins act as cellular sen-
sors that can modulate intracellular Ca2+ signaling is
now well established [3]. Mounting evidence also sup-
ports the idea that mutations in the PC1 or PC2 gene
perturb proper assembly, activity, and regulation of the
polycystin proteins. Intriguingly, PC2 loss-of-function in
modulating intracellular Ca2+ concentration may pro-
vide a possible explanation for the pathophysiology of
ADPKD [17]. Here, we showed that the PC2 subcellular
localization pattern is dynamically regulated in both
human and rat kidney cells. Dependent on cytosolic
Ca2+ increases, PC2 translocated from the cytosolic/ER
compartment to the PM. When cells were challenged
with ouabain, a treatment that has been shown to induce
InsP3R-dependent Ca
2+ oscillations in kidney cells
[14,15], an increased PM PC2 localization and PM Ca2+
permeability were observed. The PM Ca2+ permeability was
indirectly examined using Mn2+ quenching and electro-
physiology recordings are required to determine absolute
numbers. Pharmacological inhibition of key intracellular
Ca2+ release components suppressed Ca2+-mediated
PC2 trafficking, indicating a Ca2+-dependent trans-
location process. CaMK, a canonic Ca2+-activated kinase,
was necessary for PC2 translocation, whereas the PI3K or
PKC kinases contributed to a lesser extent. Mutations caus-
ing ADPKD have been reported altering the sub-cellular
PC2 localization and/or function. For example, PC2 havingthe naturally occurring pathogenic mutant R742X resides
in the PM [13], however, without having channel activity
[18]. Another pathogenic missense mutation of PC2 is
D511V [19], where a single amino acid in the third
membrane-spanning domain is mutated, results in a loss of
PC2 channel activity [3].
The subcellular localization pattern of the PC2 protein
has been a long-lasting matter of controversy [20]. In
various cell lines (LLCPK1, MDCK, HEK-293) and adult
human kidney PC2 has been detected in ER where it
function as a Ca2+ channel [13,21]. PC2 has also been
detected in the basolateral and lateral cell membrane in
adult human and rat kidney cells and collecting duct
cells where it functions as cell-cell adhesion [6,21-25]. In
primary cilium of human proximal tubule and mouse
collecting duct cells PC2 is reported as a flow-sensitive
channel [7,26,27]. These observations, and many others
that report different PC2 localization [20], support the
idea of a dynamic protein with its expression regulated
by sub-cellular mechanisms. For example, PC2 contains
an ER retention signal in its C-terminal sequence that
inhibits trafficking to the cell surface [28]. PC2 deletion
mutants for this ER retention signal constitutively trans-
locate to the PM [18]. In ER Ca2+ stores, PC2 acts as a
Ca2+-release channel that amplifies Ca2+ transients
initiated by InsP3Rs [3]. Ca
2+ releasing activity of PC2 is
regulated by Ca2+ itself through a Ca2+-induced Ca2+ re-
lease mechanism [29] that requires direct association
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intracellular Ca2+ concentration [30].
PC2 has previously been reported to be present in the
PM [22,25]. PC2 localization to the PM is then modu-
lated by chemical chaperones, proteasome inhibitors,
protein-protein interactions and phosphorylation, and
also upon massive overexpression that eventually over-
rides the ER retention machinery [6]. Under certain con-
ditions, for example when PC2 is truncated at or before
Glu787 its product is detected in the PM [13]. Traffick-
ing of PC2 in cells has also been suggested to occur
through its physical interaction with PC1 via their
C-termini, forming a heteromeric, non-selective cationic
channel complex [31]. Efficient assembly of PC1 and
PC2 appears to be essential for proper trafficking and
channel activity [32]. These previous results and the
findings presented here support the idea of a dynamic-
ally regulated subcellular localization of PC2.
Our results indicate that CaMK is an important
regulator of PC2 trafficking to the PM. Indeed, phos-
phorylation has previously been demonstrated in PC2
trafficking [13]. Two evolutionarily conserved phosphor-
ylation sites in the PC2 protein sequence were suggested
to control its subcellular localization: serine residue 76
(Ser76)/Ser80 and Ser812, which are phosphorylated by
glycogen synthase kinase 3 (GSK3) [33] and casein ki-
nase 2 (CK-2) [34], respectively. We speculate that the
PM PC2 portion might be phosphorylated differently
than ER PC2. It has been shown that PKC-dependent
phosphorylation at Ser801 is essential for a normal func-
tion of PC2 as an ER Ca2+ release channel [35].
Additionally, Never in mitosis A-related kinase 8 (Nek8),
a serine/threonine kinase that is mutated in some cases
of juvenile polycystic kidney disease, induced abnormal
PC2 phosphorylation and trafficking to primary cilia in
the kidney [36]. The Ca2+ dependent trafficking of PC2
reported herein might also play a role in the PC2 expres-
sion profile in cilia. Surprisingly little is known about
the upstream physiological stimuli activating all these
kinases to critically regulate PC2 trafficking. Whether
the Ca2+ signaling pathway presented here is the missing
upstream link in controlling CaMK, GSK-3, CK-2 or
Nek8 in PC2 trafficking remains to be further examined.
Polycystin proteins are expressed in primary cilia of
cultured renal epithelial cells, where they might function
in transducing sensory information, such as shear stress
during fluid flow [7], leading to Ca2+ influx through
mechanically sensitive channels that reside in the ciliary
membrane [37]. This Ca2+ signal is then amplified by
Ca2+ release from internal ER/SR stores and spreads to
neighboring cells through gap junctions. PC2 has been
suggested to be a mechano-sensitive channel since
mechano-transduction is abolished in the presence of a
specific PC2 blocking antibody [7] and in epithelial cellsisolated from PC1-deficient mice [7]. Intracellular Ca2+
release and PC2 trafficking to the PM may form a posi-
tive loop for Ca2+ influx and intracellular Ca2+ overload,
a condition that has been reported previously in ADPKD
progression [1,5]. However, the exact contribution of
PC2 dynamic localization to the PM in ADPKD patho-
genesis remains to be elucidated.
Our results show that endogenous agonists that
increase cytosolic Ca2+ levels, such as ouabain, ATP, or
bradykinin, induced PC2 trafficking to the PM. It
was previously reported that ouabain triggers InsP3R-
dependent intracellular Ca2+ oscillation in cultured rPT
cells [14,15]. According to the results presented here,
cells that exhibited ouabain-induced Ca2+ oscillations
had increased PM Ca2+ permeability. Other reports have
shown that cilia mechano-activation leads to ATP secre-
tion, which acts as an auto/paracrine signal through
purinergic receptor activation and intracellular Ca2+ sig-
nals [38], suggesting that both agonists may contribute
to PC2 translocation to the PM under physiopathologi-
cal conditions.Conclusion
We conclude that PC2 subcellular localization is dynam-
ically regulated through an intracellular Ca2+-dependent
pathway, which in turn could be related to cystogenesis
and ADPKD pathogenesis.
Additional files
Additional file 1: Figure S1. PC2 expression pattern in proximal tubule
cells using two different antibodies. (A-D) Immunocytochemistry of PC2
in rat proximal tubule cells treated with control (A,C) or 100 μM ouabain
(B,D) using anti-PC2 polyclonal antibodies against amino acids 103 to 203
(YCB9) or 44 to 62 on the N-terminus. Scale bars, 20 μm.
Additional file 2: Figure S2. Immunocytochemistry negative control
without primary PC2 antibody. (A-B) Immunocytochemistry staining in rat
proximal tubule cells without (A) and with (B) anti-PC2 antibody present.
Scale bars, 20 μm.
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